Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

被引：0
|
作者：
Chris H. Takimoto
Ahmad Awada
机构：
[1] South Texas Accelerated Research Therapeutics (START),Medical Oncology Clinic
[2] Jules Bordet Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 61卷
关键词：
Combination; Chemotherapy; Phase I/II clinical trials; Solid tumors; Sorafenib; Targeted agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：535 / 548
页数：13
相关论文
共 50 条
  • [1] Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents:: a review of clinical trials
    Takimoto, Chris H.
    Awada, Ahmad
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 535 - 548
  • [2] Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer
    Liu, Hongyu
    Zang, Chuanbing
    Emde, Anna
    Planas-Silva, Maricarmen D.
    Rosche, Marleen
    Kuehnl, Andrea
    Schulz, Carsten-Oliver
    Elstner, Elena
    Possinger, Kurt
    Eucker, Jan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 591 (1-3) : 43 - 51
  • [3] The anti-tumor activity of CDK2 inhibition alone or in combination with other anti-cancer agents in human cancers
    Chen, Yaoyu
    Chen, Jinhong
    Guo, Yali
    Pang, Wei
    Zhou, Tingru
    Liu, Xipan
    Schomer, Nathan
    Li, Fang
    Liang, Jiaqi
    Sheng, Qing
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [4] Clinical Trials and Approval of Anti-cancer Agents
    Iwasaki, Masaru
    Hinotsu, Shiro
    Katsura, Jun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 : i65 - i69
  • [5] SOME PROBLEMS IN THE CLINICAL TRIALS OF ANTI-CANCER AGENTS
    SCHNEIDERMAN, MA
    TAYLOR, RJ
    FAND, SB
    BIOMETRICS, 1957, 13 (02) : 244 - 245
  • [6] ANTI-CANCER AGENTS .13. SYNTHESIS AND ANTI-TUMOR ACTIVITY OF 2-IMINOCHROMENE DERIVATIVES
    OCALLAGHAN, CN
    CONALTY, ML
    PROCEEDINGS OF THE ROYAL IRISH ACADEMY SECTION B-BIOLOGICAL GEOLOGICAL AND CHEMICAL SCIENCE, 1979, 79 (06) : 87 - 98
  • [7] THE LOGISTICS OF BROADER PRE-CLINICAL EVALUATION OF POTENTIAL ANTI-CANCER AGENTS WITH REFERENCE TO ANTI-TUMOR ACTIVITY AND TOXICITY OF MITOZOLOMIDE
    BIBBY, MC
    DOUBLE, JA
    WAHED, IA
    HIRBAWI, N
    BAKER, TG
    BRITISH JOURNAL OF CANCER, 1988, 58 (02) : 139 - 143
  • [8] Impact of saffron as an anti-cancer and anti-tumor herb
    Chermahini, Siavash Hosseinpour
    Majid, Fadzilah Adibah Abd
    Sarmidi, Mohamad Roji
    Taghizadeh, Ehsan
    Salehnezhad, Saleh
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 4 (11): : 834 - 840
  • [9] CONTROVERSIES IN CLINICAL-TRIALS AND EVALUATION OF ANTI-CANCER AGENTS
    YAMAMOTO, K
    ACTA OBSTETRICA ET GYNAECOLOGICA JAPONICA, 1981, 33 (09): : 1381 - 1382
  • [10] Emerging lactic acid bacteria bacteriocins as anti-cancer and anti-tumor agents for human health
    Niamah, Alaa Kareem
    Al-Sahlany, Shayma Thyab Gddoa
    Verma, Deepak Kumar
    Shukla, Rakesh Mohan
    Patel, Ami R.
    Tripathy, Soubhagya
    Singh, Smita
    Baranwal, Deepika
    Singh, Amit Kumar
    Utama, Gemilang Lara
    Gonzalez, Monica L. Chavez
    Alhilfi, Wissal Audah Hassan
    Srivastav, Prem Prakash
    Aguilar, Cristobal Noe.
    HELIYON, 2024, 10 (17)
12345